US
IE
IN
AU
JP
BM
CA
Data demonstrated beneficial bacterial taxa persist in fecal samples from patients with rCDI despite multiple prior CDI treatments with the antibiotic standards of care, vancomycin (VAN) and/or fidaxomicin (FDX) Following acute treatment with ibezapolstat (IBZ), these beneficial microorganisms will have the opportunity to repopulate the microbiome in a beneficial way that may prevent recurrence IBZ and FDX were superior in biofilm experimental models with IBZ significantly more effective at killing C. difficile than VAN and FDX Trial start-up activities for a ground-breaking clinical trial in patients with multiply-recurrent CDI (rCDI) have been initiated with the first patient expected to enroll in the next quarter; a successful trial outcome has the potential to shift the paradigm of treatment and prevention of rCDI from two agents to one With mutually consistent feedback from... Read more
